Yuhan Corporation: Business Overview, Financials & Competitive Analysis
Yuhan Corporation scores 4/10 on the AskCyborg Cyborg Score (Mixed). Leclaza-dependent biopharma play with significant upside potential offset by high valuation risk and concentrated asset base. Yuhan Corp stock analysis reveals a mixed outlook with high valuation and weak profits contrasting with a strong balance sheet and high-potential drug, Leclaza. Yuhan Corporation is overvalued, with current market price appearing to.
What is Yuhan Corporation's industry? Yuhan Corporation (yuhan.co.kr) operates in Pharmaceuticals & Biotechnology. AskCyborg classifies Yuhan Corporation under Pharmaceuticals & Biotechnology in its company registry.
Yuhan Corporation manufactures and sells prescription drugs, over-the-counter drugs, veterinary drugs, and household goods in South Korea and internationally, and also manufactures and sells animal feed and health fun...
Cyborg Score thesis
Leclaza-dependent biopharma play with significant upside potential offset by high valuation risk and concentrated asset...
Read the full analyst-debate transcript →Get the Latest Yuhan Corporation Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeYuhan Corporation Overview
Pro stress-test →Yuhan Corporation manufactures and sells prescription drugs, over-the-counter drugs, veterinary drugs, and household goods in South Korea and internationally, and also manufactures and sells animal feed and health functional food. The company was founded in 1926 and is headquartered in Seoul, South Korea. Yuhan is one of the top Korean pharmaceutical companies, along with Celltrion, Samsung Biologics, GC Pharma, and Hanmi Pharmaceutical.
Strategic Profile
Pro stress-test →Yuhan is positioned as a smaller, innovative biopharma company with a single transformative asset, which contrasts sharply with global competitors like Pfizer, Merck, and AstraZeneca, which possess vast, diversified portfolios and multi-billion dollar R&D engines. High valuation and weak profits contrast with a strong balance sheet and high-potential drug, Leclaza.
Competitive Landscape
Pro stress-test →Yuhan is one of the top Korean pharmaceutical companies, along with Celltrion, Samsung Biologics, GC Pharma, and Hanmi Pharmaceutical. Globally, it competes against companies like Pfizer, Merck, and AstraZeneca, which possess vast, diversified portfolios and multi-billion dollar R&D engines.
Industry Context
Yuhan Corporation operates in Pharmaceuticals & Biotechnology.
Key facts
Founded: 1926 · Headquarters: Seoul, South Korea · Employees: 2066 · Revenue: $1.52B · Market cap: $5.46B